The Chinese drug price registration system is officially online, and the first batch of 9 pharmaceutical companies have completed registration.

Journalists learned from the National Medical Insurance Bureau that this morning, the "China Drug Price Registration System Release Event" jointly organized by the National Medical Insurance Bureau and the Beijing Municipal People's Government, and hosted by the Xicheng District People's Government of Beijing, was held. The National Medical Insurance Bureau officially issued the "Announcement on the Launch of Drug Price Registration Query Service," and jointly launched the China Drug Price Registration System with the Beijing Municipal People's Government. They entrusted a state-owned enterprise in Xicheng District to operate in a socialized manner, in accordance with the principles of "local acceptance, national sharing, and global openness," providing drug price registration query services both online and offline for domestic and foreign pharmaceutical companies simultaneously. It is reported that pharmaceutical companies can apply for drug price registration according to their development needs, take responsibility for the authenticity, and the operating unit will accept the registration application without interfering with the specific price level of the company's products. The registered prices are open for query by companies and globally, and holders of drug market approval can obtain multilingual query certificates, serving as valid proof of drug price registration. Nine pharmaceutical companies including China Pharmaceutical Group, Tong Ren Tang, BeiGene, Kangfang Biotech, Yifan Pharmaceuticals, Roche Pharmaceuticals, WuXi AppTec, Nanjing Xinlu, and Hengrui Pharmaceuticals conducted the first batch of drug price registration on site.